Reductions in circulating levels of IL-16, IL-7 and VEGF-A in myalgic encephalomyelitis/chronic fatigue syndrome

Cytokine

Volumn 78, Issue , 2016, Pages 27-36

  Landi, Abdolamir ^a   Broadhurst, David ^b   Vernon, Suzanne D ^c   Tyrrell, D Lorne J ^a   Houghton, Michael ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c Bateman Horne Center of Excellence   (United States)

Author keywords

Chemokine; Chronic fatigue syndrome; Cytokine; Diagnostic; Growth factor

Indexed keywords

CXCL9 CHEMOKINE; EOTAXIN; EOTAXIN 2; EOTAXIN 3; FRACTALKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 16; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 5; INTERLEUKIN 7; INTERLEUKIN 8; LYMPHOTOXIN; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 4; THYMUS AND ACTIVATION REGULATED CHEMOKINE; VASCULOTROPIN A; BIOLOGICAL MARKER; CHEMOKINE; SIGNAL PEPTIDE; VEGFA PROTEIN, HUMAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CEREBROSPINAL FLUID ANALYSIS; CHRONIC FATIGUE SYNDROME; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DOWN REGULATION; ENCEPHALOMYELITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; PERSIAN GULF SYNDROME; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SYMPTOMATOLOGY; UNITED STATES; UPREGULATION; BLOOD; CASE CONTROL STUDY; MIDDLE AGED; MULTIVARIATE ANALYSIS;

ADULT; BIOMARKERS; CASE-CONTROL STUDIES; CHEMOKINES; FATIGUE SYNDROME, CHRONIC; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-16; INTERLEUKIN-7; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84947770705     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2015.11.018     Document Type: Article

References (74)

1. Coffin J.M., Stoye J.P. Virology. A new virus for old diseases?. Science 2009, 326:530-531.
2. King C., Jason L.A. Improving the diagnostic criteria and procedures for chronic fatigue syndrome. Biol. Psychol. 2005, 68:87-106.
3. Jason L.A., Sunnquist M., Kot B., Bron A. Unintended consequences of not specifying exclusionary illnesses for systemic exertion intolerance disease. Diagnostics 2015.
4. Paprotka T., Delviks-Frankenberry K.A., Cingoz O., Martinez A., Kung H.J., Tepper C.G., et al. Recombinant origin of the retrovirus XMRV. Science 2011.
5. Knox K., Carrigan D., Simmons G., Teque F., Zhou Y., Hackett J., et al. No evidence of murine-like gammaretroviruses in CFS patients previously identified as XMRV-infected. Science 2011.
6. Simmons G., Glynn S.A., Komaroff A.L., Mikovits J.A., Tobler L.H., Hackett J., et al. Failure to confirm XMRV/MLVs in the blood of patients with chronic fatigue syndrome: a multi-laboratory study. Science 2011.
7. Steffen I., Tyrrell D.L., Stein E., Montalvo L., Lee T.H., Zhou Y., et al. No evidence for XMRV nucleic acids, infectious virus or anti-XMRV antibodies in Canadian patients with chronic fatigue syndrome. PLoS ONE 2011, 6:e27870.
8. Alter H.J., Mikovits J.A., Switzer W.M., Ruscetti F.W., Lo S.C., Klimas N., et al. A multicenter blinded analysis indicates no association between chronic fatigue syndrome/myalgic encephalomyelitis and either xenotropic murine leukemia virus-related virus or polytropic murine leukemia virus. mBio 2012, 3.
9. Morris G., Maes M. A neuro-immune model of Myalgic Encephalomyelitis/Chronic fatigue syndrome. Metab. Brain Dis. 2013, 28:523-540.
10. Nakatomi Y., Mizuno K., Ishii A., Wada Y., Tanaka M., Tazawa S., et al. Neuroinflammation in patients with chronic fatigue syndrome/myalgic encephalomyelitis: an 11C-(R)-PK11195 PET study. J. Nucl. Med.: Offic. Publ., Soc. Nucl. Med. 2014.
11. Brenu E.W., Huth T.K., Hardcastle S.L., Fuller K., Kaur M., Johnston S., et al. Role of adaptive and innate immune cells in chronic fatigue syndrome/myalgic encephalomyelitis. Int. Immunol. 2014.
12. Curriu M., Carrillo J., Massanella M., Rigau J., Alegre J., Puig J., et al. Screening NK-, B- and T-cell phenotype and function in patients suffering from Chronic Fatigue Syndrome. J. Transl. Med. 2013, 11:68.
13. Broderick G., Fuite J., Kreitz A., Vernon S.D., Klimas N., Fletcher M.A. A formal analysis of cytokine networks in chronic fatigue syndrome. Brain Behav. Immun. 2010, 24:1209-1217.
14. Patarca-Montero R., Antoni M., Fletcher M.A., Klimas N.G. Cytokine and other immunologic markers in chronic fatigue syndrome and their relation to neuropsychological factors. Appl. Neuropsychol. 2001, 8:51-64.
15. Fletcher M.A., Zeng X.R., Barnes Z., Levis S., Klimas N.G. Plasma cytokines in women with chronic fatigue syndrome. J. Transl. Med. 2009, 7:96.
16. Lombardi V.C., Hagen K.S., Hunter K.W., Diamond J.W., Smith-Gagen J., Yang W., et al. Xenotropic murine leukemia virus-related virus-associated chronic fatigue syndrome reveals a distinct inflammatory signature. In vivo 2011, 25:307-314.
17. Nakamura T., Schwander S.K., Donnelly R., Ortega F., Togo F., Broderick G., et al. Cytokines across the night in chronic fatigue syndrome with and without fibromyalgia. Clin. Vaccine Immunol.: CVI 2010, 17:582-587.
18. Natelson B.H., Haghighi M.H., Ponzio N.M. Evidence for the presence of immune dysfunction in chronic fatigue syndrome. Clin. Diagn. Lab. Immunol. 2002, 9:747-752.
19. Peterson D., Brenu E.W., Gottschalk G., Ramos S., Nguyen T., Staines D., et al. Cytokines in the cerebrospinal fluids of patients with chronic fatigue syndrome/myalgic encephalomyelitis. Mediators Inflamm. 2015.
20. Hornig M., Gottschalk G., Peterson D.L., Knox K.K., Schultz A.F., Eddy M.L., et al. Cytokine network analysis of cerebrospinal fluid in myalgic encephalomyelitis/chronic fatigue syndrome. Mol. Psychiatry 2015.
21. Hornig M., Montoya J.G., Klimas N.G., Levine S., Felsenstein D., Bateman L., et al. Distinct plasma immune signatures in ME/CFS are present early in the course of illness. Sci. Adv. 2015.
22. Irlbeck D.M., Vernon S.D., McCleary K.K., Bateman L., Klimas N.G., Lapp C.W., et al. No association found between the detection of either xenotropic murine leukemia virus-related virus or polytropic murine leukemia virus and chronic fatigue syndrome in a blinded, multi-site, prospective study by the establishment and use of the SolveCFS BioBank. BMC Res. Notes 2014, 7:461.
23. Carruthers B.M. Definitions and aetiology of myalgic encephalomyelitis: how the Canadian consensus clinical definition of myalgic encephalomyelitis works. J. Clin. Pathol. 2007, 60:117-119.
24. Fukuda K., Straus S.E., Hickie I., Sharpe M.C., Dobbins J.G., Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann. Intern. Med. 1994, 121:953-959.
25. Landi A., Weismuller T.J., Lankisch T.O., Santer D.M., Tyrrell D.L., Manns M.P., et al. Differential serum levels of eosinophilic eotaxins in primary sclerosing cholangitis, primary biliary cirrhosis, and autoimmune hepatitis. J. Interferon Cytokine Res. 2014, 34:204-214.
26. Lee J.W., Devanarayan V., Barrett Y.C., Weiner R., Allinson J., Fountain S., et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm. Res. 2006, 23:312-328.
27. Storey J.D. A direct approach to false discovery rates. J. Roy. Stat. Soc. 2002, Series B 64:479-498.
28. Broadhurst D., Kell D.B. Statistical strategies for avoiding false discoveries in metabolomics and related experiments. Metabolomics: Official J. Metabolomic Soc. 2006, 2:171-196.
29. Ellson J., Gansner E.R., Koutsofios E., North S.C., Woodhull G. Graphviz and Dynagraph - Static and Dynamic Graph Drawing Tools 2004, Springer-Verlag, Berlin/Heidelberg.
30. Hastie T., Tibshirani R., Friedman J. The Elements of Statistical Learning 2008, Springer, New York. second ed.
31. Breiman L., Friedman J., Olshen R., Stone C. Classification and Regression Trees 1984, CRC Press, Boca Raton, FL.
32. Ware J.E., Sherbourne C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care 1992, 30:473-483.
33. Aslakson E., Vollmer-Conna U., Reeves W.C., White P.D. Replication of an empirical approach to delineate the heterogeneity of chronic unexplained fatigue. Popul. Health Metrics 2009, 7:17.
34. Jason L.A., Corradi K., Torres-Harding S., Taylor R.R., King C. Chronic fatigue syndrome: the need for subtypes. Neuropsychol. Rev. 2005, 15:29-58.
35. Khaiboullina S.F., DeMeirleir K.L., Rawat S., Berk G.S., Gaynor-Berk R.S., Mijatovic T., et al. Cytokine expression provides clues to the pathophysiology of Gulf War illness and myalgic encephalomyelitis. Cytokine 2014, 72:1-8.
36. Somlyo A.P., Somlyo A.V. Signal transduction and regulation in smooth muscle. Nature 1994, 372:231-236.
37. Amiel C., Darcissac E., Truong M.J., Dewulf J., Loyens M., Mouton Y., et al. Interleukin-16 (IL-16) inhibits human immunodeficiency virus replication in cells from infected subjects, and serum IL-16 levels drop with disease progression. J. Infect. Dis. 1999, 179:83-91.
38. Thornton C.A., Holloway J.A., Shute J.K., Holloway J.W., Diaper N.D., Warner J.O. Human mid-gestation amniotic fluid contains interleukin-16 bioactivity. Immunology 2009, 126:543-551.
39. Szabo P., Zhao K., Kirman I., Le Maoult J., Dyall R., Cruikshank W., et al. Maturation of B cell precursors is impaired in thymic-deprived nude and old mice. J. Immunol. 1998, 161:2248-2253.
40. Lard L.R., Roep B.O., Toes R.E., Huizinga T.W. Enhanced concentrations of interleukin 16 are associated with joint destruction in patients with rheumatoid arthritis. J. Rheumatol. 2004, 31:35-39.
41. Kageyama Y., Ozeki T., Suzuki M., Ichikawa T., Miura T., Miyamoto S., et al. Interleukin-16 in synovial fluids from cases of various types of arthritis. Joint, Bone, Spine: Revue du Rhumatisme 2000, 67:188-193.
42. Skundric D.S., Cai J., Cruikshank W.W., Gveric D. Production of IL-16 correlates with CD4+ Th1 inflammation and phosphorylation of axonal cytoskeleton in multiple sclerosis lesions. J. Neuroinflamm. 2006, 3:13.
43. Schwab J.M., Schluesener H.J., Seid K., Meyermann R. IL-16 is differentially expressed in the developing human fetal brain by microglial cells in zones of neuropoesis. Int. J. Develop. Neurosci.: Official J. Int. Soc. Develop. Neurosci. 2001, 19:93-100.
44. Shanks L., Jason L.A., Evans M., Brown A. Cognitive impairments associated with CFS and POTS. Front. Physiol. 2013, 4:113.
45. Fry T.J., Mackall C.L. Interleukin-7: from bench to clinic. Blood 2002, 99:3892-3904.
46. Sawa Y., Arima Y., Ogura H., Kitabayashi C., Jiang J.J., Fukushima T., et al. Hepatic interleukin-7 expression regulates T cell responses. Immunity 2009, 30:447-457.
47. Watanabe M., Ueno Y., Yajima T., Iwao Y., Tsuchiya M., Ishikawa H., et al. Interleukin 7 is produced by human intestinal epithelial cells and regulates the proliferation of intestinal mucosal lymphocytes. J. Clin. Invest. 1995, 95:2945-2953.
48. Schluns K.S., Lefrancois L. Cytokine control of memory T-cell development and survival. Nat. Rev. Immunol. 2003, 3:269-279.
49. Andrew D., Aspinall R. Il-7 and not stem cell factor reverses both the increase in apoptosis and the decline in thymopoiesis seen in aged mice. J. Immunol. 2001, 166:1524-1530.
50. Tsuboi I., Morimoto K., Hirabayashi Y., Li G.X., Aizawa S., Mori K.J., et al. Senescent B lymphopoiesis is balanced in suppressive homeostasis: decrease in interleukin-7 and transforming growth factor-beta levels in stromal cells of senescence-accelerated mice. Exp. Biol. Med. 2004, 229:494-502.
51. Andrew D., Aspinall R. Age-associated thymic atrophy is linked to a decline in IL-7 production. Exp. Gerontol. 2002, 37:455-463.
52. Gruver A.L., Hudson L.L., Sempowski G.D. Immunosenescence of ageing. J. Pathol. 2007, 211:144-156.
53. Lazuardi L., Jenewein B., Wolf A.M., Pfister G., Tzankov A., Grubeck-Loebenstein B. Age-related loss of naive T cells and dysregulation of T-cell/B-cell interactions in human lymph nodes. Immunology 2005, 114:37-43.
54. Ongradi J., Kovesdi V. Factors that may impact on immunosenescence: an appraisal. Immun. Ageing: I & A 2010, 7:7.
55. Kim K., Lee C.K., Sayers T.J., Muegge K., Durum S.K. The trophic action of IL-7 on pro-T cells: inhibition of apoptosis of pro-T1, -T2, and -T3 cells correlates with Bcl-2 and Bax levels and is independent of Fas and p53 pathways. J. Immunol. 1998, 160:5735-5741.
56. Pido-Lopez J., Imami N., Andrew D., Aspinall R. Molecular quantitation of thymic output in mice and the effect of IL-7. Eur. J. Immunol. 2002, 32:2827-2836.
57. Michaelson M.D., Mehler M.F., Xu H., Gross R.E., Kessler J.A. Interleukin-7 is trophic for embryonic neurons and is expressed in developing brain. Develop. Biol. 1996, 179:251-263.
58. Reinmuth N., Liu W., Jung Y.D., Ahmad S.A., Shaheen R.M., Fan F., et al. Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival. FASEB J. 2001, 15:1239-1241.
59. Licht T., Goshen I., Avital A., Kreisel T., Zubedat S., Eavri R., et al. Reversible modulations of neuronal plasticity by VEGF. Proc. Natl. Acad. Sci. USA 2011, 108:5081-5086.
60. Zhu Y., Jin K., Mao X.O., Greenberg D.A. Vascular endothelial growth factor promotes proliferation of cortical neuron precursors by regulating E2F expression. FASEB J. 2003, 17:186-193.
61. Storkebaum E., Lambrechts D., Carmeliet P. VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. BioEssays 2004, 26:943-954.
62. Cao L., Jiao X., Zuzga D.S., Liu Y., Fong D.M., Young D., et al. VEGF links hippocampal activity with neurogenesis, learning and memory. Nat. Genet. 2004, 36:827-835.
63. Stehr A., Topel I., Muller S., Unverdorben K., Geissler E.K., Kasprzak P.M., et al. VEGF: a surrogate marker for peripheral vascular disease. Eur. J. Vasc. Endovasc. Surg.: Official J. Eur. Soc. Vasc. Surg. 2010, 39:330-332.
64. Boucher J.M., Bautch V.L. Antiangiogenic VEGF-A in peripheral artery disease. Nat. Med. 2014, 20:1383-1385.
65. Wagner P.D. The critical role of VEGF in skeletal muscle angiogenesis and blood flow. Biochem. Soc. Trans. 2011, 39:1556-1559.
66. Dobrogowska D.H., Lossinsky A.S., Tarnawski M., Vorbrodt A.W. Increased blood-brain barrier permeability and endothelial abnormalities induced by vascular endothelial growth factor. J. Neurocytol. 1998, 27:163-173.
67. Louissaint A., Rao S., Leventhal C., Goldman S.A. Coordinated interaction of neurogenesis and angiogenesis in the adult songbird brain. Neuron 2002, 34:945-960.
68. Sorenson M., Jason L., Peterson J., Herrington J., Mathews H. Brain derived neurotrophic factor is decreased in chronic fatigue syndrome and multiple sclerosis. J. Neurol. Neurophys. 2014, S12.
69. Lee D.H., Geyer E., Flach A.C., Jung K., Gold R., Flugel A., et al. Central nervous system rather than immune cell-derived BDNF mediates axonal protective effects early in autoimmune demyelination. Acta Neuropathol. 2012, 123:247-258.
70. Ortuzar N., Rico-Barrio I., Bengoetxea H., Argandona E.G., Lafuente J.V. VEGF reverts the cognitive impairment induced by a focal traumatic brain injury during the development of rats raised under environmental enrichment. Behav. Brain Res. 2013, 246:36-46.
71. Religa P., Cao R., Religa D., Xue Y., Bogdanovic N., Westaway D., et al. VEGF significantly restores impaired memory behavior in Alzheimer's mice by improvement of vascular survival. Sci. Reports 2013, 3:2053.
72. Tham E., Gielen A.W., Khademi M., Martin C., Piehl F. Decreased expression of VEGF-A in rat experimental autoimmune encephalomyelitis and in cerebrospinal fluid mononuclear cells from patients with multiple sclerosis. Scand. J. Immunol. 2006, 64:609-622.
73. Iacobaeus E., Amoudruz P., Strom M., Khademi M., Brundin L., Hillert J., et al. The expression of VEGF-A is down regulated in peripheral blood mononuclear cells of patients with secondary progressive multiple sclerosis. PLoS ONE 2011, 6:e19138.
74. Blundell S., Ray K.K., Buckland M., White P.D. Chronic fatigue syndrome and circulating cytokines: a systematic review. Brain Behav. Immun. 2015.